Obesity, inflammation, and cardiovascular risk

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 407-416

  Mathieu, P ^a,b   Lemieux, I ^a   Despres J P ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; ENERGY CONSUMPTION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MACROPHAGE; METABOLIC DISORDER; METABOLISM; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; INTRA-ABDOMINAL FAT; MACROPHAGES; OBESITY; PHENOTYPE; RISK FACTORS;

EID: 77949874469     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.311     Document Type: Review

References (57)

1. Després, J.P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881-887 (2006).
2. Mathieu, P., Pibarot, P., Larose, E., Poirier, P., Marette, A. & Després, J.P. Visceral obesity and the heart. Int. J. Biochem. Cell Biol. 40, 821-836 (2008).
3. Grundy, S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 92, 399-404 (2007).
4. Libby, P., Ridker, P.M. & Hansson, G.K. Infammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54, 2129-2138 (2009).
5. Björntorp, P. Visceral obesity: a "civilization syndrome". Obes. Res. 1, 206-222 (1993).
6. Unger, R.H. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie 87, 57-64 (2005).
7. Després, J.P. Infammation and cardiovascular disease: is abdominal obesity the missing link? Int. J. Obes. Relat. Metab. Disord. 27 (suppl. 3), S22-S24 (2003).
8. Cartier, A., Lemieux, I., Alméras, N., Tremblay, A., Bergeron, J. & Després, J.P. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J. Clin. Endocrinol. Metab. 93, 1931-1938 (2008).
9. Blackburn, P. et al. Postprandial variations of plasma infammatory markers in abdominally obese men. Obesity 14, 1747-1754 (2006).
10. Spalding, K.L. et al. Dynamics of fat cell turnover in humans. Nature. 453, 783-787 (2008).
11. Gustafson, B., Gogg, S., Hedjazifar, S., Jenndahl, L., Hammarstedt, A. & Smith, U. Infammation and impaired adipogenesis in hypertrophic obesity in man. Am. J. Physiol. Endocrinol. Metab. (2009); e-pub ahead of print 21 July 2009.
12. Matsuzawa, Y. The metabolic syndrome and adipocytokines. FEBS Lett. 580, 2917-2921 (2006).
13. Andersson, C.X., Gustafson, B., Hammarstedt, A., Hedjazifar, S. & Smith, U. Infamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab. Res. Rev. 24, 595-603 (2008).
14. Mathieu, P., Pibarot, P. & Després, J.P. Metabolic syndrome: the danger signal in atherosclerosis. Vasc. Health Risk Manag. 2, 285-302 (2006).
15. Nguyen, M.T. et al. A subpopulation of macrophages infltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282, 35279-35292 (2007).
16. Lyngsø, D., Simonsen, L. & Bülow, J. Metabolic efects of interleukin-6 in human splanchnic and adipose tissue. J. Physiol. 543 (Pt 1), 379-386 (2002).
17. Abeywardena, M.Y., Leifert, W.R., Warnes, K.E., Varghese, J.N. & Head, R.J. Cardiovascular biology of interleukin-6. Curr. Pharm. Des. 15, 1809-1821 (2009).
18. Arsenault, B.J., Pibarot, P. & Després, J.P. The quest for the optimal assessment of global cardiovascular risk: are traditional risk factors and metabolic syndrome partners in crime? Cardiology 113, 35-49 (2009).
19. Ridker, P.M. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am. J. Cardiol. 92, 17K-22K (2003).
20. Arsenault, B.J. et al. Body composition, cardiorespiratory ftness, and low-grade infammation in middle-aged men and women. Am. J. Cardiol. 104, 240-246 (2009).
21. Lakoski, S.G. et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am. Heart J. 152, 593-598 (2006).
22. Kahn, S.E. et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 33, 177-183 (2010).
23. Du Clos, T.W. & Mold, C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol. Res. 30, 261-277 (2004).
24. Devaraj, S., Xu, D.Y. & Jialal, I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398-404 (2003).
25. Chandra, R.K. Cell-mediated immunity in genetically obese C57BL/6J ob/ob) mice. Am. J. Clin. Nutr. 33, 13-16 (1980).
26. Wallace, A.M. et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104, 3052-3056 (2001).
27. Couillard, C. et al. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 21, 782-786 (1998).
28. Ouchi, N. et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100, 2473-2476 (1999).
29. Côté, M. et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J. Clin. Endocrinol. Metab. 90, 1434-1439 (2005).
30. Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y. & Walsh, K. Obesity, adiponectin and vascular infammatory disease. Curr. Opin. Lipidol. 14, 561-566 (2003).
31. Schnabel, R. et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur. Heart J. 29, 649-657 (2008).
32. Way, J.M. et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 276, 25651-25653 (2001).
33. Toussirot, E., Streit, G. & Wendling, D. The contribution of adipose tissue and adipokines to infammation in joint diseases. Curr. Med. Chem. 14, 1095-1100 (2007).
34. Reilly, M.P., Lehrke, M., Wolfe, M.L., Rohatgi, A., Lazar, M.A. & Rader, D.J. Resistin is an infammatory marker of atherosclerosis in humans. Circulation 111, 932-939 (2005).
35. Mohty, D. et al. Age-related diferences in the pathogenesis of calcifc aortic stenosis: the potential role of resistin. Int. J. Cardiol. (2009); e-pub ahead of print 20 January 2009.
36. Babaev, V.R. et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-defcient mice. Arterioscler. Thromb. Vasc. Biol. 25, 1647-1653 (2005).
37. Gavrilova, O. et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105, 271-278 (2000).
38. Park, K.W., Halperin, D.S. & Tontonoz, P. Before they were fat: adipocyte progenitors. Cell Metab. 8, 454-457 (2008).
39. Miyazaki, Y., He, H., Mandarino, L.J. & DeFronzo, R.A. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 52, 1943-1950 (2003).
40. Lincof, A.M., Wolski, K., Nicholls, S.J. & Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180-1188 (2007).
41. Lemieux, I. et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/ HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch. Intern. Med. 161, 2685-2692 (2001).
42. Rye, K.A. & Barter, P.J. Antiinfammatory actions of HDL: a new insight. Arterioscler. Thromb. Vasc. Biol. 28, 1890-1891 (2008).
43. Hansel, B. et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89, 4963-4971 (2004).
44. Barter, P.J. et al. Efects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
45. Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I. & Després, J.P. Visceral obesity: the link among infammation, hypertension, and cardiovascular disease. Hypertension 53, 577-584 (2009).
46. Mazzolai, L. et al. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/-mice. Hypertension 44, 277-282 (2004).
47. Poirier, P. et al. Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension 45, 363-367 (2005).
48. Rhéaume, C. et al. Low cardiorespiratory ftness levels and elevated blood pressure: what is the contribution of visceral adiposity? Hypertension 54, 91-97 (2009).
49. Engeli, S. et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45, 356-362 (2005).
50. Vague, J. Sexual diferentiation, a factor afecting the forms of obesity. Presse. Med. 55, 339 (1947).
51. Balkau, B. et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 116, 1942-1951 (2007).
52. Boyko, E.J., Fujimoto, W.Y., Leonetti, D.L. & Newell-Morris, L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 23, 465-471 (2000).
53. Goldberg, R.B. Cytokine and cytokine-like infammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 94, 3171-3182 (2009).
54. Karalis, K.P., Giannogonas, P., Kodela, E., Koutmani, Y., Zoumakis, M. & Teli, T. Mechanisms of obesity and related pathology: linking immune responses to metabolic stress. FEBS J. 276, 5747-5754 (2009).
55. Han, S.H., Sakuma, I., Shin, E.K. & Koh, K.K. Antiatherosclerotic and anti-insulin resistance efects of adiponectin: basic and clinical studies. Prog. Cardiovasc. Dis. 52, 126-140 (2009).
56. Chang-Chen, K.J., Mullur, R. & Bernal-Mizrachi, E. Beta-cell failure as a complication of diabetes. Rev. Endocrinol. Metab. Disord. 9, 329-343 (2008).
57. Ridker, P.M. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175-1182 (2009).